Close

Xylem

Production & Manufacturing

ADIENNE Pharma signs manufacturing deal with Selexis

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

- Advertisement -

ADIENNE Pharma & Biotech has signed a service agreement with Selexis for the development of a manufacturing cell line for one of the ADIENNE’s orphan drugs.

Selexis CEO Igor Fisch said, “Combining our expertise in difficult-to-express proteins with our SUREtechnology Platform(TM) is an important step in advancing ADIENNE’s project to the clinic.”

ADIENNE Pharma & Biotech founder and CEO Antonio Francesco Di Naro said Selexis expertise will be an added value for the company’s molecule.

Selexis is a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.

Our 2026 Media Pack offers integrated solutions to reach your audience:

Latest stories

Previous article

Indian state plans non-generic drugs procurement for government hospitals

Next article

Clarity Pharmaceuticals, Dalton Pharma sign manufacturing services contract

Related stories

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »

MORE STORIES